Regulatory Changes - The industry is experiencing a massive shift, potentially the largest in the last 50 years, due to the rescheduling of cannabis [3] - Cannabis is being reclassified from a Schedule 1 drug to a Schedule 3 drug, aligning it with substances like Tylenol with codeine or steroids [2] - This rescheduling is expected to increase access to medical research and attract more investment into the cannabis industry [2] - Companies selling cannabis may benefit from new opportunities to claim basic tax deductions that were previously unavailable [2] Healthcare Access - Dr Oz is introducing a Medicare pilot program to provide eligible seniors with access to cannabis [3] Market Impact - Cannabis stocks are reacting positively to the news [3]